Sinovac Biotech Co., Ltd.
Clinical trials sponsored by Sinovac Biotech Co., Ltd., explained in plain language.
Vaccine developer and manufacturer, known for COVID-19 vaccine CoronaVac.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Polio vaccine showdown: which sequence protects best? Results expected Sep 2026 (estimated)
- Rabies vaccine batch check: will it pass the test? Results expected Sep 2026 (estimated) 🚀 Make-or-break
- New meningitis vaccine for kids shows promise in large trial Results expected Nov 2026 (estimated) 🚀 Make-or-break
- New meningitis vaccine for toddlers shows promise in major trial Results expected Jan 2027 (estimated) 🚀 Make-or-break
- Can a vaccine shield children from severe hand, foot, and mouth disease? Results expected Jan 2027 (estimated)
-
Can a vaccine shield children from severe hand, foot, and mouth disease?
Vaccine Not yet recruitingThis trial tests an inactivated EV71 vaccine in healthy children aged 6 to 71 months. The vaccine targets enterovirus 71, a major cause of severe hand, foot, and mouth disease in the Asia-Pacific region. Each child receives two doses, 30 days apart. Researchers measure whether th…
Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Sep 03, 2026 00:00 UTC
-
New vaccine aims to shield kids from hand, foot, and mouth disease
Vaccine Not yet recruitingThis study tests a new vaccine designed to prevent hand, foot, and mouth disease (HFMD) and herpangina in children aged 6 months to 5 years. About 6,000 healthy children will receive either the vaccine or a placebo to see if it safely protects against four common virus types that…
Phase 3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Jun 27, 2026 12:39 UTC
-
New RSV mRNA vaccine enters first human safety tests
Vaccine Not yet recruitingThis early-stage trial will test the safety of a new RSV mRNA vaccine in 60 healthy adults aged 18 and older. Participants will receive either a low dose, high dose, or a placebo (saline) shot. The study aims to see if the vaccine causes any side effects, paving the way for large…
Phase 1 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Vaccine
Last updated Jun 27, 2026 09:05 UTC
-
Rabies vaccine batch check: will it pass the test?
Prevention Not yet recruitingThis study tests whether three different batches of a rabies vaccine work the same way and are safe. It involves 912 healthy adults aged 18 to 45. The goal is to make sure every batch produces a strong immune response.
Phase 3 • Sponsor: Sinovac Biotech Co., Ltd • Aim: Prevention
Last updated Jun 27, 2026 09:05 UTC